Research
Hormonal
Obesity increases the risk of cardiovascular disease and hypertension through mechanisms involving increased visceral fat, insulin resistance, and altered sympathetic nervous system activity.
Managing your body weight, especially visceral fat, is crucial for heart health. Obesity increases your risk of cardiovascular disease and hypertension through multiple mechanisms, including insulin resistance and altered sympathetic nervous system activity. Losing weight can significantly reduce this risk.
StrongSupportsVERY_HIGH confidence
The increased secretion of prothrombin activator inhibitor-1 from fat cells may play a role in the procoagulant state of obesity and, along with changes in endothelial function, may be responsible for the increased risk of cardiovascular disease and hypertension.
Why this rating
Based on large prospective cohort studies (Nurses Health Study, Framingham Study).
Source
Medical Consequences of Obesity
George A. Bray · The Journal of Clinical Endocrinology & Metabolism · 2004
DOI 10.1210/jc.2004-0535
narrative_reviewCited 1,539×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obesity increases the risk of type 2 diabetes mellitus in a curvilinear manner, with relative risk increasing 40-fold at a BMI of 35 kg/m2 compared to a BMI of 22 kg/m2.Strong
- Intentional weight loss reduces all-cause mortality by 20-25% in women aged 40-64 and lowers the risk of developing type 2 diabetes by 58% in high-risk individuals.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →